Cardiovascular Drugs Practice Questions

Q: Which of the following is used to treat severe pulmonary hypertension?

Bosentan. **Explanation:** **Bosentan** is the correct answer because it is a **non-selective endothelin receptor antagonist (ERA)**. It blocks both $ET_A$ and $ET_B$ receptors, which are responsible for the potent vasoconstrictive and proliferative effects of Endothelin-1. By inhibiting these receptors, Bosentan reduces pulmonary vascular resistance, making it a first-line oral therapy for **WHO Group 1 Pulmonary Arterial Hypertension (PAH)**. **Analysis of Incorrect Options:** * **Angiotensin I (A):** This is a precursor to Angiotensin II. It has no direct therapeutic role in pulmonary hypertension; in fact, its conversion to Angiotensin II would lead to systemic vasoconstriction. * **Omapatrilat (B):** This is a **Vasopeptidase inhibitor** that inhibits both Neprilysin and ACE. While it was studied for systemic hypertension and heart failure, it is not used for pulmonary hypertension and was never FDA-approved due to a high risk of angioedema. * **Endothelin (D):** This is a potent endogenous **vasoconstrictor**. Administering endothelin would severely worsen pulmonary hypertension by causing further narrowing of the pulmonary arteries. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Bosentan is a competitive antagonist at $ET_A$ and $ET_B$ receptors. * **Side Effects:** The most significant side effect is **Hepatotoxicity** (requires monthly LFT monitoring). It is also highly **Teratogenic** (Category X), necessitating a negative pregnancy test before starting therapy. * **Other ERAs:** **Ambrisentan** (selective $ET_A$ blocker) and **Macitentan** (tissue-selective non-selective blocker). * **Other PAH Treatments:** Sildenafil (PDE-5 inhibitor), Epoprostenol (Prostacyclin analogue), and Riociguat (Guanylate cyclase stimulator).

Q: A hypertensive patient on beta-blocker medication develops severe bradycardia. Which of the following is least likely to be the responsible agent?

Pindolol. **Explanation:** The core concept in this question is **Intrinsic Sympathomimetic Activity (ISA)**, also known as partial agonist activity. **Why Pindolol is the correct answer:** Pindolol is a non-selective beta-blocker that possesses significant **Intrinsic Sympathomimetic Activity (ISA)**. Unlike pure beta-blockers, pindolol partially stimulates beta-receptors while simultaneously blocking them from stronger catecholamine stimulation. Because it provides a low level of "background" stimulation, it causes significantly less bradycardia at rest compared to other beta-blockers. In some cases, it may even slightly increase the resting heart rate, making it the least likely agent among the choices to cause severe bradycardia. **Why the other options are incorrect:** * **Metoprolol (A) and Atenolol (D):** These are cardioselective ($\beta_1$) blockers. They lack ISA and are well-known for causing a dose-dependent decrease in heart rate (bradycardia) by blocking $\beta_1$ receptors in the SA and AV nodes. * **Nadolol (B):** This is a long-acting, non-selective beta-blocker without ISA. It is highly potent and frequently associated with significant bradycardia. **High-Yield Clinical Pearls for NEET-PG:** * **Beta-blockers with ISA:** Pindolol, Acebutolol, Alprenolol, and Oxprenolol. (Mnemonic: **P**a**A****A****O** - **P**indolol, **A**cebutolol, **A**lprenolol, **O**xprenolol). * **Clinical Use:** Drugs with ISA are preferred in hypertensive patients who have pre-existing bradycardia or a low cardiac reserve. * **Contraindication:** Beta-blockers with ISA are generally avoided in patients with angina or post-myocardial infarction because they do not reduce the resting heart rate or myocardial oxygen demand as effectively as pure antagonists.

Q: A 57-year-old lady presents with chief complaints of fatigue and a 5 kg weight gain in one month. She has a 10-year history of well-controlled hypothyroidism treated with L-thyroxine. Recently, she was started on an anti-arrhythmic drug for a cardiac condition, and her symptoms began after its initiation. What is the most likely anti-arrhythmic drug she was prescribed?

Amiodarone. **Explanation:** The patient is presenting with symptoms of **hypothyroidism** (fatigue, weight gain) despite being on stable L-thyroxine therapy. The temporal relationship between starting an anti-arrhythmic and the onset of symptoms points toward **Amiodarone**. **Why Amiodarone is the correct answer:** Amiodarone is a Class III anti-arrhythmic drug that is structurally unique because it contains approximately **37% iodine by weight**. It affects thyroid function through two primary mechanisms: 1. **Inhibition of 5’-deiodinase:** It blocks the peripheral conversion of T4 to the active T3. 2. **Wolff-Chaikoff Effect:** The high iodine content can lead to a transient or sustained inhibition of thyroid hormone synthesis. In patients with pre-existing thyroid disease (like this patient with a 10-year history), the thyroid may fail to "escape" this effect, leading to **Amiodarone-Induced Hypothyroidism (AIH)**. **Why other options are incorrect:** * **Lignocaine (Class Ib):** Primarily a sodium channel blocker used for ventricular arrhythmias; it has no effect on iodine metabolism or thyroid function. * **Procainamide (Class Ia):** Known for causing Drug-Induced Lupus Erythematosus (DILE), but it does not interfere with the thyroid axis. * **Verapamil (Class IV):** A calcium channel blocker used for supraventricular tachycardia; it does not impact thyroid hormone levels. **NEET-PG High-Yield Pearls:** * **Amiodarone-Induced Thyrotoxicosis (AIT):** Amiodarone can also cause hyperthyroidism via Type 1 (excess iodine substrate) or Type 2 (destructive thyroiditis). * **Half-life:** Amiodarone has an exceptionally long half-life (~weeks to months) due to its high lipid solubility. * **Monitoring:** Patients on Amiodarone require baseline and periodic **Thyroid Function Tests (TFTs)** and **Liver Function Tests (LFTs)**, along with monitoring for pulmonary fibrosis and corneal microdeposits.

Q: Pulsus Bigeminus is a potential side effect of which class of medications?

Cardiac glycosides. **Explanation:** **Pulsus Bigeminus** is a clinical finding where heartbeats occur in pairs—a normal sinus beat followed closely by a premature ventricular contraction (PVC), followed by a compensatory pause. **Why Cardiac Glycosides (e.g., Digoxin) are correct:** Digoxin toxicity is the most common cause of Pulsus Bigeminus. Digoxin inhibits the **Na+/K+ ATPase pump**, leading to an increase in intracellular sodium and, subsequently, intracellular calcium via the Na+/Ca2+ exchanger. While this increases contractility (positive inotropy), excessive calcium levels cause **delayed after-depolarizations (DADs)**. These DADs trigger premature ventricular beats, resulting in the characteristic bigeminal rhythm. **Why other options are incorrect:** * **Beta-adrenergic blockers:** These typically cause bradycardia or heart blocks (AV block) by slowing conduction through the AV node, but they do not typically trigger ectopic ventricular beats. * **ACE Inhibitors:** These primarily affect the renin-angiotensin system to lower blood pressure and do not have direct arrhythmogenic effects on the cardiac conduction system. * **Calcium Channel Blockers (CCBs):** Verapamil and Diltiazem slow the heart rate and can cause AV block, but they are actually used to *treat* certain arrhythmias rather than causing bigeminy. **High-Yield Clinical Pearls for NEET-PG:** * **Earliest sign of Digoxin toxicity:** Anorexia, nausea, and vomiting. * **Most common arrhythmia in Digoxin toxicity:** Ventricular Bigeminy. * **Most characteristic/specific arrhythmia:** Paroxysmal Atrial Tachycardia (PAT) with AV block. * **Electrolyte triggers:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose a patient to digoxin toxicity. * **Visual disturbance:** Xanthopsia (yellow-green halos around lights) is a classic board-style symptom of toxicity.

Q: Which of the following is NOT an adverse effect of Losartan?

Cough. **Explanation:** **Losartan** is an Angiotensin II Receptor Blocker (ARB) that selectively antagonizes the $AT_1$ receptor. **Why "Cough" is the correct answer:** Dry cough is a classic side effect of **ACE Inhibitors** (e.g., Enalapril), not ARBs. ACE inhibitors prevent the breakdown of **bradykinin** and **Substance P** in the lungs; the accumulation of these pro-inflammatory autacoids irritates the bronchial mucosa, leading to a persistent dry cough. Since Losartan acts downstream of ACE and does not interfere with bradykinin metabolism, it is characteristically "cough-neutral" and is the preferred alternative for patients who develop a cough on ACE inhibitors. **Analysis of incorrect options:** * **Angioedema:** While much rarer than with ACE inhibitors, angioedema can still occur with ARBs (likely due to $AT_2$ receptor overstimulation or indirect effects on the kinin system). * **Hyperkalemia:** Both ACE inhibitors and ARBs decrease Aldosterone secretion. Reduced aldosterone leads to potassium retention, making hyperkalemia a significant risk, especially in patients with renal impairment or those on K-sparing diuretics. * **Headache:** This is one of the most commonly reported non-specific side effects of Losartan, along with dizziness and fatigue. **High-Yield NEET-PG Pearls:** 1. **Teratogenicity:** Like ACE inhibitors, Losartan is **contraindicated in pregnancy** (causes fetal renal dysgenesis and skull hypoplasia). 2. **Uricosuric Effect:** Losartan is unique among ARBs as it inhibits the URAT1 transporter, increasing uric acid excretion. It is the drug of choice for hypertensive patients with **Gout**. 3. **First-pass metabolism:** Losartan undergoes significant metabolism to its active metabolite, **EXP3174**, which is a more potent non-competitive antagonist than the parent drug.

Q: What is the only FDA-approved therapeutic use of Endothelium-Derived Relaxing Factor?

Pulmonary hypertension in newborns. **Explanation:** **Endothelium-Derived Relaxing Factor (EDRF)** is chemically identified as **Nitric Oxide (NO)**. It is a potent endogenous vasodilator that acts by stimulating soluble guanylyl cyclase, increasing intracellular cGMP, and leading to smooth muscle relaxation. **Why Option A is Correct:** The only FDA-approved clinical use for inhaled Nitric Oxide is **Persistent Pulmonary Hypertension of the Newborn (PPHN)**. In newborns with hypoxic respiratory failure, inhaled NO acts as a **selective pulmonary vasodilator**. Because it is rapidly inactivated by binding to hemoglobin upon entering the systemic circulation, it reduces pulmonary vascular resistance without causing systemic hypotension. **Why Other Options are Incorrect:** * **Option B (Primary Pulmonary Hypertension):** While NO can be used during "vasoreactivity testing" to identify responders in adults, it is not the primary FDA-approved therapeutic treatment. Drugs like Bosentan (Endothelin antagonist) or Sildenafil (PDE-5 inhibitor) are preferred for long-term management. * **Option C (Congestive Cardiac Failure):** NO is not used here as it does not address myocardial contractility and could potentially worsen left-sided heart failure by increasing pulmonary venous return. * **Option D (Essential Hypertension):** NO is administered via inhalation and has a very short half-life (seconds). It is impractical and ineffective for treating systemic (essential) hypertension. **High-Yield NEET-PG Pearls:** * **Mechanism:** NO → ↑ cGMP → Protein Kinase G → Vasodilation. * **Diagnostic Use:** Inhaled NO is used in the cardiac cath lab to differentiate reversible from irreversible pulmonary hypertension. * **Toxicity:** Monitor for **Methemoglobinemia** and Nitrogen Dioxide (NO₂) toxicity during administration. * **Synergy:** Sildenafil potentiates the effects of NO by inhibiting the breakdown of cGMP.

Q: Which of the following drugs can cause altered taste sensation?

Captopril. **Explanation:** **Correct Option: D. Captopril** Captopril, an ACE inhibitor, is well-known for causing **dysgeusia** (altered taste sensation) or ageusia (loss of taste). This side effect is primarily attributed to the presence of a **sulfhydryl (-SH) group** in its chemical structure [1]. This group can interfere with zinc metabolism or directly affect taste bud function. While other ACE inhibitors can cause this, it is most frequently associated with Captopril [1]. **Analysis of Incorrect Options:** * **A & C (Pefloxacin and Ciprofloxacin):** These are Fluoroquinolones. Their primary side effects include GI upset, tendon rupture (Achilles tendon), and CNS stimulation. While some patients report a metallic taste with certain antibiotics (like Metronidazole or Clarithromycin), it is not a classic or high-yield side effect associated with Fluoroquinolones in the context of NEET-PG. * **B (Rifampicin):** The hallmark side effect of Rifampicin is the **orange-red discoloration** of body fluids (urine, sweat, tears). It is also a potent microsomal enzyme inducer and can cause hepatotoxicity, but it does not typically cause altered taste. **Clinical Pearls for NEET-PG:** * **ACE Inhibitor Side Effects (Mnemonic: CAPTOPRIL):** **C**ough (due to Bradykinin), **A**ngioedema, **P**roteinuria, **T**aste changes, **O**rthostatic hypotension, **P**regnancy contraindication, **R**enal artery stenosis (bilateral) contraindication, **I**ncreased Potassium (Hyperkalemia), **L**eukopenia. * **Other drugs causing metallic/altered taste:** Metronidazole, Lithium, Acetazolamide, Disulfiram, and Phenytoin. * **Zinc Deficiency:** Often presents with dysgeusia; Captopril-induced taste loss sometimes responds to zinc supplementation.

Q: Which of the following drugs releases Nitric oxide?

Hydralazine. **Explanation:** **1. Why Hydralazine is Correct:** Hydralazine is a direct-acting peripheral arterial vasodilator. Its primary mechanism involves the release of **Nitric Oxide (NO)** from the vascular endothelium, which stimulates guanylyl cyclase to increase intracellular **cGMP**. This leads to smooth muscle relaxation and vasodilation. It also inhibits calcium release from the sarcoplasmic reticulum and hyperpolarizes the membrane. **2. Why the other options are incorrect:** * **Aminophylline:** This is a methylxanthine derivative (a complex of theophylline and ethylenediamine). It acts primarily as a **non-selective phosphodiesterase (PDE) inhibitor** and adenosine receptor antagonist, used mainly in asthma/COPD, not via NO release. * **Amrinone (Inamrinone):** This is a **PDE-3 inhibitor**. It increases cAMP levels in cardiac and vascular muscle, exerting positive inotropic and vasodilator effects (inodilator). * **Sildenafil sulfate:** This is a selective **PDE-5 inhibitor**. While it *potentiates* the action of Nitric Oxide by preventing the breakdown of cGMP, it does **not** release NO itself. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-Induced Lupus Erythematosus (DILE):** Hydralazine is a classic cause, especially in "slow acetylators." * **Clinical Use:** It is a preferred drug for managing **hypertension in pregnancy** (along with Labetalol and Methyldopa). * **Reflex Tachycardia:** Because it causes significant arterial dilation, it often triggers compensatory tachycardia and fluid retention; thus, it is frequently co-administered with a Beta-blocker and a diuretic. * **Other NO donors:** Nitroglycerin, Sodium Nitroprusside (releases NO directly), and Minoxidil (though Minoxidil primarily acts via K+ channel opening).

Q: Acute anginal attack can be terminated by:

Nitroglycerin. **Explanation:** **Nitroglycerin (Option A)** is the drug of choice for terminating an acute anginal attack. It acts as a prodrug that releases **Nitric Oxide (NO)**, which stimulates guanylyl cyclase to increase cGMP levels. This leads to dephosphorylation of myosin light chains, causing potent vascular smooth muscle relaxation. Its primary benefit in angina is **venodilation**, which reduces venous return (preload) and decreases myocardial oxygen demand. When administered **sublingually**, it bypasses first-pass metabolism, providing a rapid onset of action (1–3 minutes) essential for acute relief. **Why other options are incorrect:** * **Digoxin (Option B):** A cardiac glycoside used in heart failure and atrial fibrillation. It increases myocardial contractility (positive inotropy), which actually *increases* oxygen demand and could worsen angina. * **Lignocaine (Option C):** A Class IB antiarrhythmic used for ventricular arrhythmias, particularly post-MI. It has no role in relieving myocardial ischemia or anginal pain. * **Verapamil (Option D):** A non-dihydropyridine Calcium Channel Blocker. While used for *prophylaxis* of stable and variant angina, its oral onset is too slow for terminating an acute attack, and IV use is reserved for supraventricular tachycardias. **High-Yield NEET-PG Pearls:** * **Route of Choice:** Sublingual or buccal spray for acute attacks; transdermal patches for chronic prophylaxis. * **Storage:** Nitroglycerin is volatile and light-sensitive; it must be stored in dark glass containers. * **Tolerance:** A "nitrate-free interval" (8–12 hours) is required daily to prevent tachyphylaxis. * **Contraindication:** Never co-administer with **Sildenafil** (PDE-5 inhibitors) due to the risk of severe, fatal hypotension.

Question 1

Which of the following is used to treat severe pulmonary hypertension?

Accepted Answer

Bosentan

Answer

Angiotensin I

Answer

Omapatrilat

Answer

Endothelin

Question 2

A hypertensive patient on beta-blocker medication develops severe bradycardia. Which of the following is least likely to be the responsible agent?

Accepted Answer

Pindolol

Answer

Metoprolol

Answer

Nadolol

Answer

Atenolol

Question 3

A 57-year-old lady presents with chief complaints of fatigue and a 5 kg weight gain in one month. She has a 10-year history of well-controlled hypothyroidism treated with L-thyroxine. Recently, she was started on an anti-arrhythmic drug for a cardiac condition, and her symptoms began after its initiation. What is the most likely anti-arrhythmic drug she was prescribed?

Accepted Answer

Amiodarone

Answer

Lignocaine

Answer

Procainamide

Answer

Verapamil

Question 4

Pulsus Bigeminus is a potential side effect of which class of medications?

Accepted Answer

Cardiac glycosides

Answer

Beta-adrenergic blockers

Answer

Angiotensin-converting enzyme inhibitors

Answer

Calcium channel blockers

Question 5

Which of the following is NOT an adverse effect of Losartan?

Accepted Answer

Cough

Answer

Angioedema

Answer

Hyperkalemia

Answer

Headache

Question 6

Which of the following is not a common side effect for ACE inhibitors and Angiotensin receptor blockers?

Accepted Answer

Dry cough

Answer

Postural hypotension

Answer

Hyperkalemia

Answer

None of the above

Question 7

What is the only FDA-approved therapeutic use of Endothelium-Derived Relaxing Factor?

Accepted Answer

Pulmonary hypertension in newborns

Answer

Primary pulmonary hypertension

Answer

Congestive cardiac failure

Answer

Essential hypertension in newborns

Question 8

Which of the following drugs can cause altered taste sensation?

Accepted Answer

Captopril

Answer

Pefloxacin

Answer

Rifampicin

Answer

Ciprofloxacin

Question 9

Which of the following drugs releases Nitric oxide?

Accepted Answer

Hydralazine

Answer

Aminophylline

Answer

Amrinone

Answer

Sildenafil sulfate

Question 10

Acute anginal attack can be terminated by:

Accepted Answer

Nitroglycerin

Answer

Digoxin

Answer

Lignocaine

Answer

Verapamil

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?